2-((4-(trifluoromethyl)phenyl)methoxy)acetyl chloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-((4-(trifluoromethyl)phenyl)methoxy)acetyl chloride
• 英文别名: 2-[[4-(Trifluoromethyl)phenyl]methoxy]acetyl chloride；2-[[4-(trifluoromethyl)phenyl]methoxy]acetyl chloride
• 化学式: C₁₀H₈ClF₃O₂
• 分子量: 252.621
• InChiKey: MISIZQHBNFKTEY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-((4-(trifluoromethyl)phenyl)methoxy)acetyl chloride 在 N-羟基丁二酰亚胺 、 三乙胺 、 lithium hydroxide 、 N,N'-二异丙基碳二亚胺 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 4.0h， 生成 (R)-N-(7-(3-(dimethylamino)phenoxy)-3-(3-(4-fluoropiperidin-1-yl)-3-oxopropyl)-2,5-dioxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-8-yl)-2-((4-(trifluoromethyl)benzyl)oxy)acetamide
  参考文献：
  名称：

  Discovery of 1,4-Benzodiazepine-2,5-dione (BZD) Derivatives as Dual Nucleotide Binding Oligomerization Domain Containing 1/2 (NOD1/NOD2) Antagonists Sensitizing Paclitaxel (PTX) To Suppress Lewis Lung Carcinoma (LLC) Growth in Vivo

  摘要：

  Nucleotide-binding oligomerization domain-like receptors (NLRs) are intracellular sensors of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). Previously, we reported nucleotide-binding oligomerization domain-containing protein 1 (NOD1) antagonists (II, 12) and a NOD2 antagonist (9) that sensitized docetaxel (DTX) or paclitaxel (PTX) treatment for breast or lung cancer. In this article, we describe for the first time a 1,4-benzodiazepine-2,5-dione (BZD) derivative (26bh) that acts as a dual NOD1/NOD2 antagonist and inhibits both nuclear factor kappa B (NF-kappa B) and mitogen-activated protein kinase (MAPK) inflammatory signaling, thereby sensitizing PTX to suppress Lewis lung carcinoma (LLC) growth. After investigation of the compound's cytotoxicity, a systematic structure-activity relationship (SAR) was completed and revealed several key factors that were necessary to maintain antagonistic ability. This study establishes the possibility for using adjuvant treatment to combat cancer by antagonizing both NOD1 and NOD2 signaling.

  DOI：

  10.1021/acs.jmedchem.7b00608
• 作为产物：
  描述：

  4-(三氟甲基)苄醇 在 草酰氯 、 sodium hydride 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 2-((4-(trifluoromethyl)phenyl)methoxy)acetyl chloride
  参考文献：
  名称：

  Discovery of 1,4-Benzodiazepine-2,5-dione (BZD) Derivatives as Dual Nucleotide Binding Oligomerization Domain Containing 1/2 (NOD1/NOD2) Antagonists Sensitizing Paclitaxel (PTX) To Suppress Lewis Lung Carcinoma (LLC) Growth in Vivo

  摘要：

  Nucleotide-binding oligomerization domain-like receptors (NLRs) are intracellular sensors of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). Previously, we reported nucleotide-binding oligomerization domain-containing protein 1 (NOD1) antagonists (II, 12) and a NOD2 antagonist (9) that sensitized docetaxel (DTX) or paclitaxel (PTX) treatment for breast or lung cancer. In this article, we describe for the first time a 1,4-benzodiazepine-2,5-dione (BZD) derivative (26bh) that acts as a dual NOD1/NOD2 antagonist and inhibits both nuclear factor kappa B (NF-kappa B) and mitogen-activated protein kinase (MAPK) inflammatory signaling, thereby sensitizing PTX to suppress Lewis lung carcinoma (LLC) growth. After investigation of the compound's cytotoxicity, a systematic structure-activity relationship (SAR) was completed and revealed several key factors that were necessary to maintain antagonistic ability. This study establishes the possibility for using adjuvant treatment to combat cancer by antagonizing both NOD1 and NOD2 signaling.

  DOI：

  10.1021/acs.jmedchem.7b00608

文献信息

• 拮抗NOD1/2受体信号通路的喹唑啉酮类化合物
  申请人：宁波康柏睿格医药科技有限公司

  公开号：CN113354590A

  公开（公告）日：2021-09-07

  本发明公开了拮抗NOD1/2受体信号通路的喹唑啉酮类化合物，具体公开了一类的如通式I和II所示的喹唑啉酮类化合物小分子化合物，这类喹唑啉酮类化合物的制备方法，含有这些化合物的药物组合物，以及这类化合物通过拮抗NOD1/2信号传导通路的激活，可用于机体的免疫治疗，尤其是可以用于肿瘤的治疗，属于医药技术领域。
• Enantiomeric enrichment of cyanohydrins
  申请人：BEND RESEARCH, INC.

  公开号：EP0561535A2

  公开（公告）日：1993-09-22

  A method of enantiomerically enriching chiral cyanohydrins is disclosed that involves selective cleavage of the unwanted enantiomer into its cleavage products HCN and the corresponding aldehyde or ketone by use of an enantioselective dehydrocyanation catalyst, coupled with simultaneous removal of at least one of the dehydrocyanation products.

  本发明公开了一种对映体富集手性氰醇的方法，包括使用对映体选择性脱氢氰化催化剂，将不需要的对映体选择性裂解为其裂解产物 HCN 和相应的醛或酮，同时去除至少一种脱氢氰化产物。
• Thermostable omega-transaminases
  申请人：Pannuri Sachin

  公开号：US20060228788A1

  公开（公告）日：2006-10-12

  Thermostable omega-transaminases, particularly thermostable omega-transaminases which have a high reaction rate and which are tolerant to high concentrations of donor amine, can be used to enrich enantiomerically a mixture of chiral amines or to synthesize stereoselectively one of a pair of chiral amines in which the amino group is bound to a non-terminal, chirally substituted, carbon atom.

  恒温欧米伽-反式胺酶，尤其是反应速度快、耐受高浓度供体胺的恒温欧米伽-反式胺酶，可用于富集手性胺混合物的对映体，或立体选择性合成一对手性胺中的一个，其中的氨基与非末端的手性取代碳原子结合。
• Nonpeptidic quinazolinone derivatives as dual nucleotide-binding oligomerization domain-like receptor 1/2 antagonists for adjuvant cancer chemotherapy
  作者：Yao Ma、Jingshu Yang、Xiduan Wei、Yameng Pei、Jingjia Ye、Xueyuan Li、Guangxu Si、Jingyuan Tian、Yi Dong、Gang Liu

  DOI：10.1016/j.ejmech.2020.112723

  日期：2020.12

  Nucleotide-binding oligomerization domain-containing protein 1 and 2 (NOD1/2) receptors are potential immune checkpoints. In this article, a quinazolinone derivative (36b) as a NOD1/2 dual antagonist was identified that significantly sensitizes B16 tumor-bearing mice to paclitaxel treatment by inhibiting both nuclear factor κB (NF-κB) and mitogen-activated protein kinase inflammatory signaling that mediated by NOD1/2.
• Enantiomeric enrichment and stereoselective synthesis of chiral amines
  申请人：CELGENE CORPORATION

  公开号：EP0404146B1

  公开（公告）日：1996-03-20